Indications and uses
For relief of cold and flu-like symptoms such as nasal congestion, runny or blocked nose, post nasal drip, sore throat, cough and headache. For optimal results, use at first sign of cold or flu-like symptoms.
For relief of cold and flu-like symptoms such as nasal congestion, runny or blocked nose, post nasal drip, sore throat, cough and headache. For optimal results, use at first sign of cold or flu-like symptoms.
Adults and children 4 years and older. Spray 3 times to throat and swallow; also spray once into each nostril, let drip, then swallow. Use up to 4 times daily, up to 5 days. Store at room temperature in a cool, dry place.
Eucalyptol 3x HPUS
Eucalyptus globulus 3x HPUS
Gaultheria 3x HPUS
Mentholum 4x HPUS
Sambucus nigra 2x HPUS
The letters HPUS indicate that this ingredient is officially included in the Homeopathic Pharmacopoeia of the United States.
For relief of cold and flu-like symptoms such as nasal congestion, runny or blocked nose, post nasal drip, sore throat, cough and headache. For optimal results, use at first sign of cold or flu-like symptoms.
Citric acid, ethanol, glycerin, poloxamer 407, sodium benzoate, sodium chloride, sorbitol, thymol, water, xylitol.
call (888) 407-2816
FluNadaCarton2014.jpg FluNadaLabel2014.jpg
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 54705-160-01 | 2021-01-29 | C162847 | 48780-1 | ba0f9c33-4962-a910-e053-dadaa90a0b85 | FluNada Cold and Flu Relief - Drug Facts Label |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54705-160-01 | FluNadaCold and Flu Relief | 1 in 1 CARTON | SPRAY, METERED | 1 | 7 | |
| 54705-160-20 | FluNadaCold and Flu Relief | 20 mL in 1 BOTTLE, SPRAY | SPRAY, METERED | 20 | 7 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 54705-160 | FLUNADA COLD AND FLU RELIEF (EUCALYPTOL, EUCALYPTUS GLOBULUS WHOLE, MENTHOL, SAMBUCUS NIGRA WHOLE, METHYL SALICYLATE) SPRAY, METERED [FLUTRENDS INTERNATIONAL CORPORATION] | 7 | Legacy NDC, 2 package rows | 20191217_0ada95d1-23fa-4baa-8594-75a39b5b4b9c.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| EUCALYPTOL | ACTIVE INGREDIENT | RV6J6604TK | 6 | |
| EUCALYPTUS GLOBULUS WHOLE | ACTIVE INGREDIENT | SI1P2XF3M3 | 6 | |
| MENTHOL | ACTIVE INGREDIENT | L7T10EIP3A | 6 | |
| METHYL SALICYLATE | ACTIVE INGREDIENT | LAV5U5022Y | 6 | |
| SAMBUCUS NIGRA WHOLE | ACTIVE INGREDIENT | 4X6JT95SYN | 6 | |
| EUCALYPTOL | ACTIVE MOIETY | RV6J6604TK | 6 | |
| EUCALYPTUS GLOBULUS WHOLE | ACTIVE MOIETY | SI1P2XF3M3 | 6 | |
| MENTHOL | ACTIVE MOIETY | L7T10EIP3A | 6 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 6 | |
| SAMBUCUS NIGRA WHOLE | ACTIVE MOIETY | 4X6JT95SYN | 6 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 6 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 6 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 6 | |
| POLOXAMER 407 | INACTIVE INGREDIENT | TUF2IVW3M2 | 6 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 6 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 6 | |
| SORBITOL | INACTIVE INGREDIENT | 506T60A25R | 6 | |
| THYMOL | INACTIVE INGREDIENT | 3J50XA376E | 6 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 6 | |
| XYLITOL | INACTIVE INGREDIENT | VCQ006KQ1E | 6 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54705-160 | 54705-160-20, 54705-160-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| WATER | 059QF0KO0R | IACT |
| ALCOHOL | 3K9958V90M | IACT |
| XYLITOL | VCQ006KQ1E | IACT |
| POLOXAMER 407 | TUF2IVW3M2 | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| SORBITOL | 506T60A25R | IACT |
| SODIUM CHLORIDE | 451W47IQ8X | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| THYMOL | 3J50XA376E | IACT |
| EUCALYPTOL | RV6J6604TK | ACTIB |
| EUCALYPTUS GLOBULUS WHOLE | SI1P2XF3M3 | ACTIB |
| MENTHOL | L7T10EIP3A | ACTIB |
| SAMBUCUS NIGRA WHOLE | 4X6JT95SYN | ACTIB |
| METHYL SALICYLATE | LAV5U5022Y | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / INTRAVESICAL | 7892 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | INJECTION / INTRAVENOUS | 864 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | TABLET, COATED / ORAL | 12.96 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | SUSPENSION / ORAL | 45000 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | PASTE, DENTIFRICE / DENTAL | 14 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TOPICAL | 2445 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | CREAM / TOPICAL | 13 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SYSTEM / IONTOPHORESIS | 168.1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | TABLET, EFFERVESCENT / ORAL | 460 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / BUCCAL | NA | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LIQUID / TOPICAL | 2.5 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | MOUTHWASH / BUCCAL | 200 mg/1ml | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | CONCENTRATE / ORAL | 1800 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY, METERED / NASAL | 36 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / SUBCUTANEOUS | 90 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / ORAL | 315 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | CAPSULE, EXTENDED RELEASE / ORAL | 40 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SPONGE / TOPICAL | 2 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / TOPICAL | 0.2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / OPHTHALMIC | 10 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | LIQUID / INTRAVENOUS | 6320 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 1800 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / IONTOPHORESIS | 0.02 %w/v | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | GEL / PERIODONTAL | 155 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | CONCENTRATE / ORAL | 20 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | INJECTION / INTRAMUSCULAR | NA | ||
| SORBITOL | SORBITOL | 506T60A25R | SUSPENSION / RECTAL | 46.18 %w/v | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / INTRAMUSCULAR | 400 mg | ||
| POLOXAMER 407 | POLOXAMER 407 | TUF2IVW3M2 | CAPSULE / ORAL | 468 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | TABLET, COATED / ORAL | 0.2 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 385 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / SUBCUTANEOUS | 450 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBMUCOSAL | 17 mg | ||
| XYLITOL | XYLITOL | VCQ006KQ1E | SUSPENSION, EXTENDED RELEASE / ORAL | 9000 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / SUBCUTANEOUS | 15 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRAPERITONEAL | 226 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / EPIDURAL | 0.9 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION, EXTENDED RELEASE / ORAL | 2000 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | POWDER, FOR SOLUTION / TOPICAL | 40 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | GRANULE, FOR SUSPENSION / ORAL | 113 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION/ DROPS / TOPICAL | 0.86 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / RETROBULBAR | 648 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER, FOR SOLUTION / TOPICAL | NA | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SYSTEM / IONTOPHORESIS | 0.2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRADERMAL | 7 mg | ||
| SORBITOL | SORBITOL | 506T60A25R | LIQUID / TOPICAL | 1 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION, CONCENTRATE / INTRAVENOUS | NA | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / ORAL | 210 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / SUBCUTANEOUS | 0.8 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACARDIAC | 70 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | OINTMENT / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / RECTAL | 7 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 99d3bc09-e021-66dc-e053-2995a90aaacc | 0ada95d1-23fa-4baa-8594-75a39b5b4b9c | 2019-12-16 | Warnings | 99d3bc09-e021-66dc-e053-2995a90aaacc 0ada95d1-23fa-4baa-8594-75a39b5b4b9c |
Adverse event summaries are temporarily unavailable. Other product information remains available.